Abbott On Track To Reach U.S. DES Market By Late 2007 With ZoMaxx

Abbott is counting on the deliverability of its ZoMaxx ABT-578-eluting stent to differentiate it from established competitors in the U.S. market

More from Archive

More from Medtech Insight